Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)

Industry Research by Koncept Analytics

Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook ----------------------------------------(2017-2025)

November 2017

Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)

1

Executive Summary Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease caused by the accumulation of a surfactant (proteins and lipids) accumulated in small air bags of the lung, called alveoli, which interfere with breathing.

PAP condition occurs in 6 individuals per million and is considered an orphan disease.

Pulmonary surfactant is produced by the body in healthy people and patients with PAP, which is a mixture of phospholipids and synthesized proteins. These surfactants form cell lines to prevent the collapse of the pulmonary membranes by reducing the surface tension. This pulmonary surfactant must be constantly replaced to maintain the active and functional layer and to prevent excessive layering. The exact reason for the accumulation of excess surfactants is unknown. This requires a signal and messenger molecule called granulocyte-macrophage colony stimulating factor (GM-CSF) to stimulate alveolar macrophages to work properly and maintain a normal level of surfactant in the cells. This process of maintaining a stable state is known as homeostasis and requires that GM-CSF stimulate alveolar macrophages to remove excess surfactant.

Treatment of PAP depends on the form of PAP and age of a patient with PAP and severity of the disease. WLL is a standard treatment for PAP and the only treatment which has shown improved symptoms and oxygenation in patients. Another treatment of PAP includes using recombinant granulocyte colony stimulating factor (GM-CSF) which is given by nose or with a subcutaneous injection which is not approved yet.

The global PAP market is expected to show significant growth after the introduction of the molgradex drug in 2020. The growth of market will mainly be driven by huge unmet demand, increasing male population, rising middle-aged population and increasing health expenditure. However, the growth of the market will be hindered by the absence of effective diagnostics and costly drugs.

The report “Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)� analyzes the development of this market, with focus on the US, Europe, and Japan region. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. A key upcoming player in the market i.e. Savara Inc. is being profiled along with its key financials and strategies for growth. The report contains a comprehensive analysis of the global PAP market along with the study of the regional markets.

Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)

2

Increasing PAP prevalence and health care expenditure supported the growth of global PAP market.

Global PAP Patient Prevalence Forecast (2017-2025)

Thousands

• The global PAP prevalence is anticipated to reach … thousand in year 2025, increasing from …thousand patients in 2017, recording growth at a CAGR of …% for the period spanning 2017-2025.

• The addressable population for Molgradex is expected to reach …thousand in 2025, increasing from ….thousand, growing at a rate of …% for the period spanning 20172025.

• In 2020, the prevalence of PAP in Europe with ….% share of total prevalence, followed by the US and Japan with …..% and …..% shares respectively.

2017 2018 2019 2020 2021 2022 2023 2024 2025

Global PAP Prevalence Forecast by Region (2020)

Thousands

Global Molgradex Addressable Population Forecast (2017-2025)

2017 2018 2019 2020 2021 2022 2023 2024 2025

Europe

Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)

US

Japan

3

Strong R&D efforts and launch of Molgradex drug will drive growth of global PAP drug market…

The US Patient on Molgradex Therapy Forecast (2020-2025)

Thousands

• The US patients on molgradex therapy is likely to reach …thousand in 2025, increasing from ….thousand in 2020, as the product is expected to be launched in the market in year 2020.

• In Europe, Molgradex revenue is anticipated to reach US$.... million in 2025, increasing from US$... million, growing at a CAGR of ….% for the period spanning 2020-2025.

• In Japan, the addressable population for Molgradex treatment is anticipated to reach … in 2025, increasing from … in 2017, growing at a CAGR of …% for the period spanning 2017-2025.

2020

2021

2022

2023

2024

2025

Europe Molgradex Revenue Forecast (2020-2025)

US$ Million

Japan Molgradex Addressable Population Forecast (2017-2025)

2020

2021

2022

2023

2024

2025

2017 2018 2019 2020 2021 2022 2023 2024 2025

Global Pulmonary Alveolar Proteinosis (PAP) Market: Industry Analysis & Outlook (2017-2025)

4

Contact Us:

Disclaimer

This is a licensed product of Koncept Analytics. You cannot reproduce, publish, distribute, publicly display, sell or create other works from this report or use them in any way for commercial purpose without our prior permission. Further, you cannot copy this material, by any means (including electronic copies), for distribution to others unless you have purchased the corporate license of this report.

We believe the sources are reliable, but Koncept Analytics does not warranty the accuracy or completeness of the data. The data presented in the report is updated at the publication date but is subject to change at subsequent releases. All possible efforts have been made to ensure accuracy of data. However, investors should not completely rely on the information given in this report and must make decisions based on their own investment strategy, risk management and capital adequacy.

For Report Purchase Click Below: http:// www.konceptanalytics.com/Researchreport/global-pulmonary-alveolar-proteinosis-pap-market-industry-analysis-outl ook-2017-2025-26471.aspx Koncept Analytics CS-36, First Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T: +91-120-4130959 M: +91-9871694789 vikas@konceptanalytics.com www.konceptanalytics.com